Patents by Inventor Xiaotian Zhu

Xiaotian Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240208960
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: wherein A, L, R1, R2, R3, and n are described herein.
    Type: Application
    Filed: July 28, 2023
    Publication date: June 27, 2024
    Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Xiaotian Zhu
  • Patent number: 11958850
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: April 16, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela V. West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
  • Publication number: 20240066031
    Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
    Type: Application
    Filed: September 26, 2023
    Publication date: February 29, 2024
    Inventors: Zhilong Hu, Hu He, Fei Zhang, Wenge Zhong, Xiaotian Zhu
  • Publication number: 20240033264
    Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
    Type: Application
    Filed: September 26, 2023
    Publication date: February 1, 2024
    Applicant: QILU REGOR THERAPEUTICS INC.
    Inventors: Zhilong Hu, Hu He, Fei Zhang, Wenge Zhong, Xiaotian Zhu
  • Publication number: 20230339896
    Abstract: The invention provides a compound represented by structural formula (I) or formula (II), or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPKl activity.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 26, 2023
    Inventors: Wenge Zhong, Xiaotian Zhu, Song Feng, Lei Wu, Wei Huang, Hao Liu, Rongqiang Liu, Kate Xin Wen, Hua Zhou
  • Patent number: 11753404
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: wherein A, L, R1, R2, R3, and n are described herein.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: September 12, 2023
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Xiaotian Zhu
  • Publication number: 20230174512
    Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
    Type: Application
    Filed: May 4, 2021
    Publication date: June 8, 2023
    Inventors: Zhilong Hu, Hu He, Fei Zhang, Wenge Zhong, Xiaotian Zhu
  • Publication number: 20230102829
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Application
    Filed: August 31, 2021
    Publication date: March 30, 2023
    Inventors: WEI-SHENG HUANG, YONGJIN GONG, FENG LI, NICHOLAS E. BENCIVENGA, DAVID C. DALGARNO, ANNA KOHLMANN, WILLIAM C. SHAKESPEARE, RANNY M. THOMAS, XIAOTIAN ZHU, ANGELA V. WEST, WILLMEN YOUNGSAYE, YUN ZHANG, TIANJUN ZHOU
  • Publication number: 20220389037
    Abstract: Provided herein is a compound represented by structural formula (I-0) or formula (II): or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPK1 activity.
    Type: Application
    Filed: July 3, 2020
    Publication date: December 8, 2022
    Inventors: Wenge Zhong, Xiaotian Zhu, Song Feng, Lei Wu, Wei Huang, Hao Liu, Rongqiang Liu, Kate Xin Wen, Hua Zhou
  • Publication number: 20220296595
    Abstract: Provided is a compound represented by structural formula (I), or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
    Type: Application
    Filed: May 5, 2020
    Publication date: September 22, 2022
    Inventors: Zhilong Hu, Hu He, Fei Zhang, Xiaotian Zhu, Wenge Zhong
  • Publication number: 20220081440
    Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Application
    Filed: October 12, 2021
    Publication date: March 17, 2022
    Inventors: Dong Zou, Wei-Sheng Huang, R. Mathew Thomas, Jan Antoinette C. Romero, Jiwei Qi, Yihan Wang, Xiaotian Zhu, William C. Shakespeare, Rajeswari Sundaramoorthi, Chester A. Metcalf, III, David C. Dalgarno, Tomi K. Sawyer
  • Publication number: 20220064144
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: (I) where A, L, R1, R2, R3, and n are described herein.
    Type: Application
    Filed: August 12, 2021
    Publication date: March 3, 2022
    Inventors: Nicholas E. BENCIVENGA, David C. DALGARNO, Joseph M. GOZGIT, Wei-Sheng HUANG, Anna KOHLMANN, Feng LI, Jiwei QI, William C. SHAKESPEARE, Ranny M. THOMAS, Yihan WANG, Yun ZHANG, Xiaotian ZHU
  • Publication number: 20220033392
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: wherein A, L, R1, R2, R3, and n are described herein.
    Type: Application
    Filed: April 9, 2021
    Publication date: February 3, 2022
    Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Xiaotian Zhu
  • Patent number: 11180482
    Abstract: The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R1, R2, R3, R4, R5, R6, R16, R17, X1, X2, X3, X4, m, and n are described herein.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: November 23, 2021
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Wei-Sheng Huang, Yun Zhang, Willmen Youngsaye, Xiaotian Zhu, Erin Geno
  • Publication number: 20210304195
    Abstract: A method for blockchain payment channel network multi-path routing based on a genetic algorithm includes: S1, constructing a directed graph according to a structure of a payment channel network; S2, based on the payment channel network, generating an initial population; S3, taking a total fee charge of the k payment paths corresponding to the each individual as an adaptability, and selecting a parent based on the adaptability; S4, based on the adaptability, performing a cross operation and a mutation operation on the parent; S5, when a population converges or a number of iterations reaches a preset threshold, determining the total fee charge for the each individual in a last-generation population, and selecting an individual with the smallest total fee charge as an optimal solution under a current k value; and, S6, selecting a target payment path from a plurality of selected payment paths.
    Type: Application
    Filed: October 20, 2020
    Publication date: September 30, 2021
    Applicant: WUHAN UNIVERSITY
    Inventors: Yanjiao CHEN, Xiaotian ZHU
  • Patent number: 11117883
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: (I) where A, L, R1, R2, R3, and n are described herein.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: September 14, 2021
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Yun Zhang, Xiaotian Zhu
  • Patent number: 11001580
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other-threonine kinase mediated diseases, having the Formula: (I) wherein A, L, R1, R2, R3, and n are described herein.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: May 11, 2021
    Assignee: ARIAD PHARMACEUTICALS, INC.
    Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Xiaotian Zhu
  • Publication number: 20200317705
    Abstract: The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.
    Type: Application
    Filed: November 1, 2019
    Publication date: October 8, 2020
    Inventors: Yihan Wang, Wei-Sheng Huang, Shuangying Liu, William C. Shakespeare, Ranny M. Thomas, Jiwei Qi, Feng Li, Xiaotian Zhu, Anna Kohlmann, David C. Dalgarno, Jan Antoinette C. Romero, Dong Zou
  • Patent number: 10785572
    Abstract: A terminal component is applied to a speaker, and includes two terminals, a sleeve seat, and two fixing heads. Each terminal includes a terminal head and a terminal body. The sleeve seat includes two terminal blocks. The two terminal blocks respectively accommodate the two terminal bodies, so that the two terminal heads are exposed outside the sleeve seat. The two fixing heads are respectively combined with the two terminal heads, to respectively fasten two wires to the two terminals.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: September 22, 2020
    Assignee: Tymphany Acoustic Technology (Huizhou) Co., Ltd.
    Inventors: ZhiWen Chen, XiaoTian Zhu
  • Patent number: 10766208
    Abstract: An electronic device and an information processing method are provided. The electronic device includes: a maintaining body configured to maintain a relative position relationship between the electronic device and the at least one part of the body of the user in a case that the electronic device is in a maintained state; a display connected to the maintaining body and including at least two display regions; a first sensor configured to sense a motion parameter of the at least one part of the body in a case that the at least one part of the body of the user moves; and a processor configured to determine a motion state of the at least one part of the body based on the motion parameter and adjust a display mode of the display based on the motion state according to a first adjusting strategy.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: September 8, 2020
    Assignees: Beijing Lenovo Software Ltd., Lenovo (Beijing) Co., Ltd.
    Inventors: Jie Xia, Xiaotian Zhu, Yan Gao